Gene–Disease Research Guide
NPAS2 associated diseases research links a core circadian transcription factor to tissue-specific phenotypes rather than one uniform disease mechanism. NPAS2 can partner with BMAL1 to regulate E-box-containing targets. Experimental studies support an NPAS2–HES1 axis in activated hepatic stellate cells and an NPAS2–CDC25A mechanism in hepatocellular carcinoma, while human cancer associations outside these models remain context dependent. Creative Biolabs can connect gene–disease evidence review, RNA profiling, and gene-edited models with timing-aware functional readouts.
Entity Identity
NPAS2 is a bHLH-PAS transcription factor and a component of circadian transcriptional networks. In functional studies, sampling time, synchronization, and model state can influence whether a target or phenotype is detected.
Research-use boundary: Disease associations on this page are intended to help plan mechanistic and validation studies. They are not diagnostic or treatment recommendations.
| Field | Current research reference |
|---|---|
| Official symbol / name | NPAS2 — neuronal PAS domain protein 2. |
| Human identifiers | NCBI Gene 4862; HGNC 7895; aliases include MOP4 and PASD4. |
| Core molecular role | bHLH-PAS transcription factor; can heterodimerize with BMAL1 and regulate circadian / E-box-linked transcription. |
| Disease evidence emphasized here | Liver fibrosis: hepatic stellate-cell activation via HES1; HCC: cell survival and proliferation via CDC25A-linked signaling. |
| Last scientific check | November 3, 2026; timing conditions and tissue/model context should be recorded when comparing studies. |
Biological Context
For NPAS2, the biological question should specify both the target pathway and the timing context. A single untimed expression measurement may be insufficient for a circadian-regulated mechanism.
NPAS2 can participate in circadian transcriptional feedback and regulate E-box-containing targets in a context-dependent manner.
In fibrogenic liver models, NPAS2 up-regulation in activated hepatic stellate cells was linked to HES1 transcription and extracellular-matrix responses.
In HCC models, NPAS2 promoted proliferation and inhibited mitochondria-dependent apoptosis through CDC25A-linked effects on CDKs and BCL-2.
Evidence Map
The liver-fibrosis and HCC studies provide direct perturbation evidence, whereas broader circadian-gene cancer associations are better used as hypothesis-generating context.
| Association / mechanism | Evidence type | What is supported | What still needs validation |
|---|---|---|---|
| NPAS2 in liver fibrosis | Mouse fibrosis models plus hepatic stellate-cell experiments | NPAS2 was increased after fibrogenic injury; knockout reduced fibrosis; HES1 was identified as a transcriptional mediator. | Confirm in the selected injury model and cell source; account for timing and activation state. |
| NPAS2 in HCC | Human tumor association, cell perturbation, xenograft and promoter mechanism | NPAS2 promoted HCC survival; CDC25A was a downstream transcriptional target in the reported model. | Reproduce in the project genotype/model and distinguish direct transcriptional effects from secondary cell-cycle changes. |
| NPAS2 in breast/colorectal cancer | Human expression/genotype association studies | NPAS2 expression or variants have been associated with prognosis/risk in selected cohorts. | Cohort associations are not a universal direction-of-effect and should not be treated as mechanistic proof. |
| Circadian transcription biology | Established clock-gene literature | NPAS2 is a circadian bHLH-PAS transcription factor. | Synchronization and sampling time can strongly influence expression and downstream readouts. |
Study Design
A useful NPAS2 experiment pre-defines when samples are collected and which direct target or phenotype will determine whether the hypothesis is supported.
Question: Does NPAS2 perturbation change HES1 and hepatic stellate-cell activation?
Useful readouts: NPAS2/HES1 RNA and protein, α-SMA/ACTA2, collagen/ECM markers, morphology, and rescue.
Decision: Tests whether the NPAS2–HES1 model operates in the selected HSC system.
Question: Does NPAS2 modulation alter CDC25A, cell-cycle activity, and apoptosis?
Useful readouts: CDC25A, CDK-related readouts, BCL-2/apoptosis markers, proliferation, and rescue.
Decision: Supports or weakens CDC25A dependence in the project model.
Question: Do NPAS2 and downstream targets vary across synchronized sampling points?
Useful readouts: Time-course RNA/protein and phenotype measurements.
Decision: Determines whether a static endpoint is masking or exaggerating a circadian effect.
Validation Workflow
The workflow can combine synchronized baseline profiling, perturbation, time-course sampling, target validation, and phenotype rescue. Gene knockout or CRISPR-assisted cell-line development may be used when a stable perturbation is needed.
| Stage | Recommended approach | Controls / QC | Primary output |
|---|---|---|---|
| 1. Model and timing setup | Select HSC, HCC, or other relevant model; define synchronization and sampling schedule. | Cell identity; baseline oscillation/NPAS2 expression; matched sampling. | Timing-aware assay plan. |
| 2. Perturbation | Knockout/knockdown, overexpression, or targeted variant design. | Independent reagents/clones; genotype/expression confirmation. | Verified NPAS2 modulation. |
| 3. Target-gene readout | Measure HES1, CDC25A, or other pre-specified target(s). | Time-matched controls; RNA/protein orthogonal readout. | Evidence of target-gene response. |
| 4. Phenotype | Fibrosis/activation, proliferation, cell cycle, or apoptosis. | Dose/time controls; assay-specific positive control. | Functional effect size and reproducibility. |
| 5. Rescue / timing validation | Restore downstream mediator or repeat across sampling times. | Matched construct/expression and repeated timing. | Mechanistic and temporal interpretation. |
Project Readiness
Provide enough context to distinguish an expression-association study from a causal gene-function study. Missing items can often be addressed during technical review.
| Input | Required / optional | Preferred information | Why it matters |
|---|---|---|---|
| Research objective | Required | Mechanistic question, disease context, and decision to make | Determines whether the project is association, perturbation, or rescue focused. |
| Gene / construct status | Required | Reference sequence, variant, plasmid, guide design, or existing cell line | Defines what can enter the workflow immediately and what must be built. |
| Model | Required | Cell type, organoid/iPSC context, animal model, species, or primary material | Disease relevance and readout interpretation are model dependent. |
| Controls | Required | Wild-type, non-targeting, vehicle, matched rescue, and/or pathway control | Separates gene-specific effects from editing, delivery, or background effects. |
| Existing data | Optional | Expression, sequencing, imaging, phenotype, or prior perturbation data | Can reduce redundant work and guide assay selection. |
| Target readout | Required | Molecular, cellular, pathway, or phenotype endpoint | Lets the study define a stop/go criterion before experiments begin. |
Interpretation Boundaries
NPAS2 and downstream genes can vary with circadian state. Record synchronization, sampling time, medium changes, and treatment timing.
A mechanism in hepatic stellate cells is not automatically transferable to HCC, breast cancer, or another tissue.
Human prognostic or variant associations can motivate a study but do not establish a direct transcriptional mechanism.
This page supports experimental design; it is not intended for clinical risk prediction or treatment selection.
Research Support
Use these modules to move from a literature-supported hypothesis to a defined perturbation, model, and measurable endpoint. The final scope should be agreed for the selected model and materials.
You provide: Model, synchronization plan, perturbation, sampling points, and target pathways.
Scope to discuss: Whether targeted or broader profiling is needed and how timing should be normalized.
Outputs to agree: Expression matrices, QC, time-course plots, and interpretation notes.
You provide: Reference sequence, model, perturbation goal, and downstream phenotype.
Scope to discuss: Knockout/knock-in strategy, validation, and timing-aware assay readiness.
Outputs to agree: Model material, genotype/QC information, and agreed follow-up readouts.
You provide: HCC or other model, NPAS2 status, target gene, and phenotype hypothesis.
Scope to discuss: Assay timing, apoptosis/proliferation readouts, and rescue design.
Outputs to agree: Comparative functional data and analysis.
Selected Reading
NCBI. NPAS2 neuronal PAS domain protein 2. Gene ID 4862; updated 2026. https://www.ncbi.nlm.nih.gov/gene/4862.
Yang X, et al. NPAS2 contributes to liver fibrosis by direct transcriptional activation of Hes1 in hepatic stellate cells. Molecular Therapy — Nucleic Acids. 2019;18:1009-1022. https://doi.org/10.1016/j.omtn.2019.10.025.
Yuan P, et al. NPAS2 promotes cell survival of hepatocellular carcinoma by transactivating CDC25A. Cell Death & Disease. 2017;8(3):e2704. https://doi.org/10.1038/cddis.2017.131.
Yi C, et al. The circadian gene NPAS2 is a novel prognostic biomarker for breast cancer. Breast Cancer Research and Treatment. 2010;120(3):663-669. https://doi.org/10.1007/s10549-009-0484-0.
FAQ
Tell us about your project, and our experts will get back to you with a customized quote and proposal.
